Recovery ⏱ Half-life: Short. Experimental

Kristagen

Kristagen (EW Dipeptide)

Updated March 15, 2026

Evidence at a Glance

Regulatory statusExperimental
Khavinson immune 'bioregulator' tripeptide (Glu-Asp-Pro); evidence almost entirely from one Russian lab.
Human evidenceAnecdotal only
Animal evidenceLimited

Kristagen is a synthetic Khavinson bioregulator tripeptide promoted for immune support, but its evidence is almost entirely low-quality work from a single Russian institute with no independent clinical validation.

What the research does not support

  • It has no independent, peer-reviewed human trials outside Vladimir Khavinson's own institute.
  • It is not approved as a drug in the US or EU and is not a proven immune or anti-aging therapy.
  • The tissue-specific gene-regulation and lifespan-extension claims are hypotheses, not established human science.
Half-Life
Short.
Mol. Weight
~333 g/mol

What is Kristagen?

Kristagen is a next-generation thymus-targeting dipeptide bioregulator designed to restore and maintain immune function through epigenetic modulation of T-cell development pathways.

Research Applications

Immune restoration, thymic function, age-related immune decline, and T-cell maturation support.

Dosage Information (Research Use)

Capsules: 1-2 daily for 10-30 day courses. Research use only.

Reconstitution & Handling

Capsules taken orally. Injectable: standard reconstitution.

Half-Life & Pharmacokinetics

Short.

Reported Observations in Literature

Generally well-tolerated.

Key Research References

  • Khavinson VK. “Short peptides modulate immune function.” Bull Exp Biol Med. 2010

How Kristagen Works

Kristagen targets thymic tissue gene expression to support T-lymphocyte maturation and immune function. As a dipeptide, it crosses biological membranes efficiently and acts at the epigenetic level to normalize immune-related gene expression patterns.

Research Findings

Alternative to Thymalin and Vilon for thymus-focused immune support. Part of the newer generation of Khavinson bioregulators with improved oral bioavailability.

Dosage & Administration

Capsules: 1-2 daily for 10-30 day courses. Research use only.

Safety & Side Effects

Generally well-tolerated.

Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Sequence Glu-Trp
Molecular Weight ~333 g/mol
Half-Life Short.
Available Sizes 5mg, capsules
Storage Room temperature for capsules. Lyophilized: -20°C.

Key Research References

  • Khavinson VK. "Short peptides modulate immune function." Bull Exp Biol Med. 2010

Related Peptides

View all →
Lanreotide
Recovery
Long-acting somatostatin analog for acromegaly and neuroendocrine tumors with convenient self-injectable depot formulation.
View Profile →
LL-37
Recovery
Human host defense peptide (cathelicidin) with antimicrobial, immunomodulatory, and wound healing properties.
View Profile →
Cartalax
Recovery
Tripeptide bioregulator researched for cartilage tissue support and chondrocyte activity in joint degeneration models.
View Profile →